Apriem Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Apriem Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-6,000	Closed	-$146K	–	353
2018 Q2	$146K	Buy	+6,000	New	+$122K	0.03%	146
2015 Q4	–	Sell	-100	Closed	-$6K	–	567
2015 Q3	$6K	Buy	+100	New	+$6.48K	﹤0.01%	397
2014 Q4	–	Sell	-49,130	Closed	-$2.64M	–	551
2014 Q3	$2.64M	Sell	49,130 -2,900	-6%	-$154K	1.01%	38
2014 Q2	$2.73M	Sell	52,030 -1,000	-2%	-$51.1K	1.04%	36
2014 Q1	$2.8M	Sell	53,030 -885	-2%	-$40.9K	1.06%	33
2013 Q4	$2.16M	Sell	53,915 -9,115	-14%	-$359K	0.85%	42
2013 Q3	$2.38M	Sell	63,030 -3,750	-6%	-$146K	1.03%	37
2013 Q2	$2.62M	Buy	+66,780	New	+$2.6M	1.28%	30

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Apriem Advisors's TEVA Position: Q3 2018 in Review

Apriem Advisors sold out of Teva Pharmaceuticals (TEVA) in Q3 2018, closing a stake of 6,000 shares — an estimated $146K sold.

Apriem Advisors first reported a position in TEVA in Q2 2013 and held it in 8 quarters. The position peaked at $2.8M in Q1 2014. 557 funds tracked by Wall St. Rank hold TEVA as of Q3 2018.

Apriem Advisors reported no remaining Teva Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Apriem Advisors sold 6,000 Teva Pharmaceuticals shares in Q3 2018, an estimated $146K.
Apriem Advisors first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 8 quarters.
Apriem Advisors's Teva Pharmaceuticals position peaked at $2.8M in Q1 2014.
557 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2018.

Based on Apriem Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.